224 related articles for article (PubMed ID: 25712974)
21. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai.
Zeng M; El Khatib NF; Tu S; Ren P; Xu S; Zhu Q; Mo X; Pu D; Wang X; Altmeyer R
J Clin Virol; 2012 Apr; 53(4):285-9. PubMed ID: 22265829
[TBL] [Abstract][Full Text] [Related]
22. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice.
Li HY; Han JF; Qin CF; Chen R
Vaccine; 2013 Jul; 31(32):3281-7. PubMed ID: 23726823
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the antibody response against EV71 capsid proteins in Chinese individuals by NEIBM-ELISA.
Ding Y; Chen X; Qian B; Wu G; He T; Feng J; Gao C; Wang L; Wang J; Li X; Cao M; Peng H; Zhao C; Pan W
Sci Rep; 2015 May; 5():10636. PubMed ID: 26023863
[TBL] [Abstract][Full Text] [Related]
24. EV71 infection correlates with viral IgG preexisting at pharyngo-laryngeal mucosa in children.
Xue J; Li Y; Xu X; Yu J; Yan H; Yan H
Virol Sin; 2015 Apr; 30(2):146-52. PubMed ID: 25813631
[TBL] [Abstract][Full Text] [Related]
25. Incidence rates of enterovirus 71 infections in young children during a nationwide epidemic in Taiwan, 2008-09.
Lee MS; Chiang PS; Luo ST; Huang ML; Liou GY; Tsao KC; Lin TY
PLoS Negl Trop Dis; 2012; 6(2):e1476. PubMed ID: 22348156
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibodies for diagnosis of enterovirus 71.
Xu L; Huang KJ; Ho TS; Liu CC; Lee YR; Lin CY; Shiuan D; Jiang XH
Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):386-94. PubMed ID: 24328741
[TBL] [Abstract][Full Text] [Related]
27. Bedside immunochromatographic test for enterovirus 71 infection in children.
Huang KY; Yang S; Tsao KC; Chen CJ; Hsieh YC; Chiu CH; Hsieh JY; Yang JY; Huang YC
J Clin Virol; 2013 Nov; 58(3):548-52. PubMed ID: 24084600
[TBL] [Abstract][Full Text] [Related]
28.
Caine EA; Osorio JE
J Virol; 2017 Mar; 91(5):. PubMed ID: 27974562
[TBL] [Abstract][Full Text] [Related]
29. Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months.
Jin P; Li J; Zhang X; Meng F; Zhou Y; Yao X; Gan Z; Zhu F
Hum Vaccin Immunother; 2016 Apr; 12(4):916-21. PubMed ID: 26751765
[TBL] [Abstract][Full Text] [Related]
30. Development of a sensitive and specific epitope-blocking ELISA for universal detection of antibodies to human enterovirus 71 strains.
He F; Kiener TK; Lim XF; Tan Y; Raj KV; Tang M; Chow VT; Chen Q; Kwang J
PLoS One; 2013; 8(1):e55517. PubMed ID: 23383215
[TBL] [Abstract][Full Text] [Related]
31. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints.
Zhu W; Jin P; Li JX; Zhu FC; Liu P
Expert Rev Vaccines; 2017 Sep; 16(9):945-949. PubMed ID: 28548626
[TBL] [Abstract][Full Text] [Related]
32. Human enterovirus 71 strains in the background population and in hospital patients in Finland.
Honkanen H; Oikarinen S; Pakkanen O; Ruokoranta T; Pulkki MM; Laitinen OH; Tauriainen S; Korpela S; Lappalainen M; Vuorinen T; Haapala AM; Veijola R; Simell O; Ilonen J; Knip M; Hyöty H
J Clin Virol; 2013 Apr; 56(4):348-53. PubMed ID: 23261080
[TBL] [Abstract][Full Text] [Related]
33. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
34. Development of a high-throughput assay for measuring serum neutralizing antibody against enterovirus 71.
Huang ML; Chiang PS; Luo ST; Liou GY; Lee MS
J Virol Methods; 2010 Apr; 165(1):42-5. PubMed ID: 20036286
[TBL] [Abstract][Full Text] [Related]
35. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection.
Cao RY; Dong DY; Liu RJ; Han JF; Wang GC; Zhao H; Li XF; Deng YQ; Zhu SY; Wang XY; Lin F; Zhang FJ; Chen W; Qin ED; Qin CF
PLoS One; 2013; 8(5):e64024. PubMed ID: 23700449
[TBL] [Abstract][Full Text] [Related]
36. Comparison of clinical features between coxsackievirus A2 and enterovirus 71 during the enterovirus outbreak in Taiwan, 2008: a children's hospital experience.
Chen SP; Huang YC; Li WC; Chiu CH; Huang CG; Tsao KC; Lin TY
J Microbiol Immunol Infect; 2010 Apr; 43(2):99-104. PubMed ID: 20457425
[TBL] [Abstract][Full Text] [Related]
37. Generation and characterization of a protective mouse monoclonal antibody against human enterovirus 71.
Deng YQ; Ma J; Xu LJ; Li YX; Zhao H; Han JF; Tao J; Li XF; Zhu SY; Qin ED; Qin CF
Appl Microbiol Biotechnol; 2015 Sep; 99(18):7663-71. PubMed ID: 25967656
[TBL] [Abstract][Full Text] [Related]
38. Viral and host factors that contribute to pathogenicity of enterovirus 71.
Huang HI; Weng KF; Shih SR
Future Microbiol; 2012 Apr; 7(4):467-79. PubMed ID: 22439724
[TBL] [Abstract][Full Text] [Related]
39. Clinical and virological features of enterovirus 71 infections in Denmark, 2005 to 2008.
Badran SA; Midgley S; Andersen P; Böttiger B
Scand J Infect Dis; 2011 Aug; 43(8):642-8. PubMed ID: 21526904
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors.
Cao RY; Han JF; Jiang T; Tian X; Yu M; Deng YQ; Qin ED; Qin CF
J Clin Virol; 2011 Aug; 51(4):246-9. PubMed ID: 21641277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
